JP2023508327A5 - - Google Patents

Info

Publication number
JP2023508327A5
JP2023508327A5 JP2022538216A JP2022538216A JP2023508327A5 JP 2023508327 A5 JP2023508327 A5 JP 2023508327A5 JP 2022538216 A JP2022538216 A JP 2022538216A JP 2022538216 A JP2022538216 A JP 2022538216A JP 2023508327 A5 JP2023508327 A5 JP 2023508327A5
Authority
JP
Japan
Prior art keywords
cancer
unsubstituted
substituted
product according
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022538216A
Other languages
English (en)
Japanese (ja)
Other versions
JP7794448B2 (ja
JP2023508327A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065401 external-priority patent/WO2021127039A1/en
Publication of JP2023508327A publication Critical patent/JP2023508327A/ja
Publication of JP2023508327A5 publication Critical patent/JP2023508327A5/ja
Application granted granted Critical
Publication of JP7794448B2 publication Critical patent/JP7794448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538216A 2019-12-20 2020-12-16 組み合わせ Active JP7794448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951991P 2019-12-20 2019-12-20
US62/951,991 2019-12-20
PCT/US2020/065401 WO2021127039A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (3)

Publication Number Publication Date
JP2023508327A JP2023508327A (ja) 2023-03-02
JP2023508327A5 true JP2023508327A5 (cg-RX-API-DMAC7.html) 2023-12-25
JP7794448B2 JP7794448B2 (ja) 2026-01-06

Family

ID=76478158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538216A Active JP7794448B2 (ja) 2019-12-20 2020-12-16 組み合わせ

Country Status (12)

Country Link
US (1) US20230068370A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069241A4 (cg-RX-API-DMAC7.html)
JP (1) JP7794448B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220119658A (cg-RX-API-DMAC7.html)
CN (1) CN115087447A (cg-RX-API-DMAC7.html)
AU (1) AU2020407514B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022012278A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165350A1 (cg-RX-API-DMAC7.html)
IL (1) IL294074A (cg-RX-API-DMAC7.html)
MX (1) MX2022007629A (cg-RX-API-DMAC7.html)
TW (1) TWI895318B (cg-RX-API-DMAC7.html)
WO (1) WO2021127039A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
CN116462687B (zh) * 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
WO2023147297A2 (en) * 2022-01-25 2023-08-03 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095250A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Combination cancer therapy of wee1 and mtor inhibitors
TWI784255B (zh) * 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CN109843882A (zh) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
UA125824C2 (uk) * 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US11479555B2 (en) * 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
BR112020018286A2 (pt) * 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas

Similar Documents

Publication Publication Date Title
JP2023507797A5 (cg-RX-API-DMAC7.html)
JP7348906B2 (ja) フェロトーシス誘導活性を有する化合物およびそれらの使用方法
TWI874834B (zh) 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
JP2023512113A5 (cg-RX-API-DMAC7.html)
CN114599361A (zh) Prmt5抑制剂的药物组合物
TWI755788B (zh) 類鐸受體促效劑
AU2022376939A1 (en) Combination therapy for treating abnormal cell growth
JP2023508325A5 (cg-RX-API-DMAC7.html)
JP2019510832A5 (cg-RX-API-DMAC7.html)
JP2025037892A (ja) ピロロピリミジンitk阻害剤
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2023508328A5 (cg-RX-API-DMAC7.html)
EP4288057A1 (en) Combination therapy for treating abnormal cell growth
RU2007134396A (ru) Химические соединения
EP3472162A1 (en) Heteroaryl estrogen receptor modulators and uses thereof
JP2023508332A5 (cg-RX-API-DMAC7.html)
US10654867B2 (en) Heteroaryl estrogen receptor modulators and uses thereof
JP2015166354A (ja) 増殖性疾患治療用非対称ピロロベンゾジアゼピン−二量体
ES2987356T3 (es) Compuestos antiproliferación y usos de los mismos
JPWO2020032105A5 (cg-RX-API-DMAC7.html)
KR20080033501A (ko) 증식성 질환 또는 염증의 치료를 위한3,11b-시스-디히드로테트라베나진
US20190117663A1 (en) Compositions and methods for treating cancer
RU2024112238A (ru) Применение комбинированной терапии для лечения рака
NZ790033A (en) Combinations
NZ790033B2 (en) Combinations